Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2025Open Access

Dual EZH1/2 inhibition enhances DNMT inhibitor efficacy in colon cancer through targeting H3K27me1

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlison A. ChomiakAWAshley K. WisemanJHJoel Hrit

Discussion

Loading...

Member takes

Overview

Experimental analysis reveals that dual EZH1/2 targeting improves tumor suppressor gene expression, highlighting potential for combination therapies.

Key Points

  • Combined EZH1/2 inhibition significantly enhances tumor suppressor gene re-expression in colon cancer cells.
  • EZH1/2 inhibitors reduce all three H3K27 methylation states, whereas EZH2-selective inhibitors preserve H3K27me1.
  • The study employed comprehensive pharmacologic screening and proteomic analyses to understand these mechanisms.
  • These findings support advancing dual EZH1/2 inhibitors for synergistic epigenetic therapy in colon cancer.

Cite This Study

Chomiak et al. (2025) studied this question.

synapsesocial.com/papers/68d439fa713b0b5dfea79e28https://doi.org/10.1101/2025.09.16.676613
View Full Paper
Ask AI
Bookmark
Share